FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

APPELL DAVID

2. Date of Event Requiring Statement (MM/DD/YYYY)
5/15/2019 

3. Issuer Name and Ticker or Trading Symbol

PARALLAX HEALTH SCIENCES, INC. [PRLX]

(Last)        (First)        (Middle)

28 W 36TH STREET, 8TH FL

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Chief Operating Officer /

(Street)

NEW YORK, NY 10018       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
COMMON STOCK (RESTRICTED)   (1) 750000   (2) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
STOCK OPTIONS   (1) 5/15/2019   5/15/2024   COMMON STOCK   750000   (3) $0.25   D    
STOCK OPTIONS   (1)   (4) 5/15/2024   COMMON STOCK   2250000   (4) $0.25   D    

Explanation of Responses:
(1)  Granted pursuant to Employment Agreement effective May 15, 2019.
(2)  Total restricted stock grant 3,000,000 common shares, of which 750,000 shares vests immediately; 750,000 shares will vest when the Company becomes EBITDA positive; 750,000 shares will vest when the Company reaches $5 million in gross revenues, or $1 million in monthly revenue; and 750,000 shares will vest when the Company reaches $10 million in gross revenues or $2 million in monthly revenue.
(3)  Vests upon execution of Employment Agreement effective May 15, 2019.
(4)  Vests monthly over 24 months.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
APPELL DAVID
28 W 36TH STREET, 8TH FL
NEW YORK, NY 10018


Chief Operating Officer

Signatures
DAVID APPELL 6/13/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Parallax Health Sciences (CE) (USOTC:PRLX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Parallax Health Sciences (CE)
Parallax Health Sciences (CE) (USOTC:PRLX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Parallax Health Sciences (CE)